Core Insights - The A-share market concluded the first half of 2025 with a structural market trend, showing significant performance divergence among public funds, with an average return of 4.13% and over 87% of funds achieving positive returns [2][3] - The top-performing funds were primarily focused on the pharmaceutical and biotechnology sectors, while some funds heavily invested in new energy and artificial intelligence themes faced performance challenges [2][3] Fund Performance Overview - The top fund, Huatai Hong Kong Advantage Selection A, achieved a remarkable return of 86.48%, while the bottom fund, Qianhai Kaiyuan Artificial Intelligence A, recorded a loss of -20.57%, resulting in a performance gap of 107 percentage points [2][3][5] - The top 30 funds exhibited three notable characteristics: a strong rise of North Exchange theme funds, widespread success of pharmaceutical theme funds, and robust performance of Hong Kong Stock Connect innovative drug ETFs [3][5] Top 30 Funds Summary - The top three funds were: 1. Huatai Hong Kong Advantage Selection A (86.48%) 2. CITIC Construction Investment North Exchange Selection Two-Year Open A (82.45%) 3. Great Wall Pharmaceutical Industry Selection A (75.18%) [4][5] - The North Exchange 50 Index rose approximately 39.45% in the first half of the year, with related theme funds dominating the top ten performance rankings [3][5] Bottom 30 Funds Summary - The bottom fund, Qianhai Kaiyuan Artificial Intelligence A, had a return of -20.57%, with most underperforming funds being mixed and stock funds, showing losses between -12.43% and -20.57% [6][7] - The underperforming funds were heavily concentrated in technology and AI sectors, which faced significant downturns, contrasting with the strong performance of healthcare and innovative drug sectors in top-performing funds [8][9] Market Outlook - The A-share market is expected to present a "volatile upward" trend in the second half of 2025, supported by a series of domestic growth policies and monetary easing [11][12] - Investment strategies should balance high-growth sectors with stable dividend assets, focusing on innovative drugs and technology while considering potential external uncertainties [12]

此外，长城医药产业精选A、中银港股通医药A等两只基金半年回报均超70%。 2025年上半年最后一个交易日（6月30日）收官，主动权益类基金（含普通股票型基金、偏股混合型基 金和灵活配置型基金）半年业绩排名也浮出水面。 Wind数据显示，业绩表现较好的主动权益类基金（年内回报以A份额为主）主要集中在北交所及医药主 题。其中，半年"冠军基"由中信建投北交所精选两年定开A斩获，截至6月30日收盘，该基金今年以来 回报高达82.45%，也是唯一一只半年回报超80%的主动权益类基金。 展望下半年，多家基金公司认为，得益于整体估值水平处于历史低位，且我国财政政策、 货币政策持续发力，A股市场下半年的投资机会仍值得关注。同时，长期来看，优质A股和海外中国资 产赴港上市都将提升港股资产的吸引力。从行业来看，下半年基金公司普遍关注科技、创新药、新消费 等板块。 北交所、医药主题基金业绩表现佳 前海开源旗下基金垫底 上半年，A股、港股市场主要指数均飘红收盘。 Wind数据显示，截至6月30日，上证指数、深证成指、创业板指年内分别涨2.76%、0.48%和0.53%。主 要主题指数中，北证50指数大幅上涨，半年涨39.45%。 港 ...

医药主题和北交所主题表现突出 今年上半年，A股市场呈现结构性行情。截至6月27日收盘，上证指数累计上涨2.16%。权益类基金业绩 同步回暖，数据显示，截至6月26日，在7881只普通股票型、偏股混合型及灵活配置型基金中，6085只 实现正收益，占比超七成。 细分赛道中，医药主题基金表现尤为突出。华安医药生物A以75.91%的收益率领跑，中银港股通医药A 收益率为72.28%。此外，永赢医药创新智选A、华安医药生物A、平安医药精选A、平安医疗健康A、富 国医药创新A、鹏华医药科技A收益率均超过50%。 北交所主题基金同样亮点纷呈。中信建投北交所精选两年定开A收益率为80.71%，华夏北交所创新中小 企业精选、万家北交所慧选等多只产品收益率超50%，资金对北交所赛道的关注度显著提升。 与之形成对比的是人工智能主题基金的回调。前海开源人工智能A、万家人工智能C年内收益率分别 为-22.69%、-16.02%，反映出前期热门赛道在市场风格切换下的阶段性调整压力。整体来看，上半年基 金业绩分化加剧，行业配置差异成为收益关键变量。 结构性机会为下半年投资关键 "回顾近几个月中国权益市场的表现，可以感受到，中国市场在全球宏 ...